Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.71 |
| ▸ | ITK | Q08881 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 6/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.66 |
| ▸ | JAK2 | O60674 | 2/20 | 0.66 |
| ▸ | TYK2 | P29597 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | CLK2 | P49760 | 2/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | CHUK | O15111 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311148 | 1.00 | FGFR1 (1.00) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3532060 | 0.85 | CHEK1 (0.79) | FGFR1FLT1PDPK1CDK2CHEK1 | |
| SCHEMBL17583341 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3533024 | 0.85 | PDPK1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3536504 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL17556295 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL29381764 | 0.85 | FGFR1 (0.73) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL4918041 | 0.84 | PDPK1 (0.76) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL3541234 | 0.84 | ITK (0.71) | FGFR1FLT1PDPK1ITKCDK2 | |
| SCHEMBL5951751 | 0.84 | PDPK1 (0.80) | FGFR1FLT1PDPK1ITKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270720-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-08-15 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-114728132-B | Injection system and method of use thereof | 梅里特斯英国第二有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-116600752-B | Motorized injection system and method of use | 梅里特斯英国第二有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240270720-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-08-15 | — | — | US | disclosed |
| US-20240270720-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-08-15 | — | — | US | disclosed |
| US-20240270720-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-08-15 | — | — | US | disclosed |
| CN-116600752-A | Motorized injection system and method of use | 梅里特斯英国第二有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023287128-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287128-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-01-19 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4031214-A1 | INJECTION SYSTEMS AND METHODS OF THEIR USE | Bullseye Therapeutics, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728132-A | Injection system and method of use | 梅拉格特克斯治疗学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270720-A1 | INDAZOLE YL BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | FLT3, JAK2, JAK3 | FGFR1 101/4885FLT1 752/4885PDPK1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.